External Beam Radiation Therapy for Granuloma Faciale: A Contemporary Approach and Clinical Lessons From a Refractory Case Authors: Renée Duvenage, Jacques D. Hill Published: 2026 Introduction Granuloma faciale (GF) is a rare benign dermatosis characterized histologically by a dense dermal inflammatory infiltrate and a Grenz zone, a narrow area of uninvolved papillary dermis separating the epidermis from the infiltrate.1, 2, 3 While GF predominantly affects middle-aged men, recent data have expanded its epidemiologic profile to include women and extrafacial presentations.4, 5, 6 Clinically, lesions present as red-brown or violaceous plaques, nodules, or papules primarily on sun-exposed facial skin.5 The etiology of GF remains unclear, although hypotheses include a localized type III hypersensitivity reaction with immune complex deposition and actinic damage as potential contributors.3,4,6,7 There is no standardized treatment, and conventional approaches, including topical corticosteroids, dapsone, laser ablation, surgical excision, and radiation, are associated with high recurrence rates and potential cosmetic compromise.1, 2, 3, 4,6, 7, 8 Due to its rarity, the role of radiation therapy (RT) has been minimally explored, with only sparse reports in the historical and modern literature.9, 10, 11, 12 We report the first case of GF managed with modern computed tomography-simulated electron beam RT and Monte Carlo dosimetry, allowing critical reflection on efficacy and limitations. Case Report A 65-year-old Caucasian woman presented to a tertiary radiation oncology clinic with a cosmetically distressing and steroid-refractory facial lesion. The lesion, which had emerged 2 years prior, had initially responded to intralesional corticosteroids but had progressed in size and symptomatology over the previous 6 months (Figure 1, Figure 2). Her past medical history included treated early-stage right breast cancer, hypertension, type 2 diabetes, obstructive sleep apnea, and multiple allergies. On examination, the lesion was a 40 × 40 mm raised, erythematous plaque with violaceous borders located on the right medial cheek (Fig. 2).Figure 1Frontal view of granuloma faciale prior to radiation therapy.Figure 1 dummy alt textFigure 2Right cheek lesion before initial treatment, showing erythema and nodular thickening.Figure 2 dummy alt text Frontal view of granuloma faciale prior to radiation therapy. Right cheek lesion before initial treatment, showing erythema and nodular thickening. Histopathology from 3 separate punch biopsies demonstrated a dense, mixed-cell perivascular infiltrate extending into the subcutis, consistent with GF.2,3 Due to steroid treatment resistance, the patient was offered surgical resection but declined, prompting RT referral. A consensus approach was obtained at a radiation oncology departmental peer review meeting. The initial external beam RT (EBRT) plan involved 6 Gy in 6 fractions (1 Gy per fraction, 3 times weekly) delivered with 6 MeV electrons prescribed to the 90% isodose line. Planning was guided by computed tomography simulation, clinical marking, and use of a 5-mm custom bolus (Fig. 3). The plan was generated using a Monte Carlo electron algorithm (Fig. 4), ensuring accurate dosimetry, sparing of deeper structures, and optimization to spare the right orbit.Figure 3Clinical set up with field markings and nasal packing prior to treatment.Figure 3 dummy alt textFigure 4Axial computed tomographic slice showing electron beam dose distribution using 6 MeV prescribed to the 90% isodose line.Figure 4 dummy alt text Clinical set up with field markings and nasal packing prior to treatment. Axial computed tomographic slice showing electron beam dose distribution using 6 MeV prescribed to the 90% isodose line. At the 4-week follow-up, mild improvement was observed, with lesion size reduced to 35 mm and slight flattening at the periphery. Given the incomplete response, an additional course was prescribed as a stepwise adaptive approach (Fig. 5) of 40 Gy in 20 fractions with a midtreatment break of 1 week to allow for clinical assessment. The dose fractionation chosen reflects similar treatment paradigms that have been successfully employed in the treatment of keloid scars or psoriasis.13,14 Due to marginal clinical response at the midtreatment break, the decision was made to proceed to the total dose of 40 Gy. The treatment was well tolerated, with only grade 1 dermatitis and nasal mucositis reported.Figure 5Frontal view at pre-retreatment review (after a limited initial response).Figure 5 dummy alt text Frontal view at pre-retreatment review (after a limited initial response). However, at 80 days after completion, the lesion had recurred with increasing erythema, induration, and pruritus. The case was reviewed at a multidisciplinary meeting, and surgical excision with skin grafting was recommended. Discussion GF is a rare chronic dermatosis with a complex inflammatory etiology, often resistant to conventional therapies. Unlike GF, benign fibroproliferative disorders such as keloids show predictable radiation sensitivity.13,14 A systematic review by Renz et al15 demonstrated that doses around 20 Gy are sufficient for keloid control postexcision, significantly below the 40 Gy used in our case. The persistence of GF despite higher radiation suggests intrinsic radiation resistance exceeding that of keloid tissue biology. GF may also share features with hidradenitis suppurativa (HS), another chronic inflammatory dermatosis.16 Although rare, EBRT has been used historically in HS, yielding partial symptomatic relief.17 The limited efficacy in HS underscores the notion that the inflammatory and immune-driven pathology of GF may mitigate radiation sensitivity.17 Although surgical excision, laser ablation, and topical immunotherapies are commonly used, they frequently fail to achieve durable control.7 Here, we document the only known case of GF treated with modern EBRT, using Monte Carlo-based planning and image guidance. Despite escalation to 40 Gy in 20 fractions, the lesion recurred within 12 weeks, reinforcing the need for prudent therapeutic targeting. Surgical excision remains the only potentially curative intervention, with its success dependent on complete excision with acceptable cosmetic outcome. Pulsed dye laser and CO₂ laser have shown limited and often temporary responses.1,7 These approaches can ablate the lesion but may require repeated treatments and come with a risk of pigmentary changes or scarring.7 Likewise, topical and systemic agents, including dapsone and corticosteroids, yield variable results due to their anti-inflammatory and immunomodulatory properties. Although relapses are frequent after discontinuation, systemic side effects (hemolysis, especially in G6PD deficiency) limit their long-term use.1,7 Ultimately, the outcomes remain unpredictable in refractory GF.1,5,7 This places RT in a cautious, tertiary role when other treatments fail or are declined. While historical literature mentions GF management using superficial x-ray or radium therapy, outcomes have often been equivocal, with many reports lacking dose or technique specifics.9, 10, 11, 12,18 The 1952 case of Peck et al,9 for example, described 6 fractions of 100 Roentgen (∼1 Gy) with no clinical benefit. More recently, Mertens et al19 reported a case resistant to a single institution’s RT protocol. Despite the limited historical success of RT in GF, it was considered a viable alternative in this case due to the patient’s decision to decline surgical excision at the time of referral. Surgery is often curative for isolated lesions, particularly when cosmetically feasible, but carries risks of scarring, infection, and potential for incomplete removal, especially in facial sites. The patient expressed concern regarding surgical morbidity and opted for a noninvasive approach. This clinical scenario necessitated the exploration of other modalities, including EBRT. RT was selected in consultation with a multidisciplinary team, with recognition that historical outcomes had been inconsistent. However, most prior attempts involved outdated techniques or low-dose regimens, often lacking detailed planning or image guidance. In contrast, our case employed modern simulation, bolus placement, electron planning with Monte Carlo algorithms, and image-guided treatment delivery to maximize conformality and minimize toxicity. The total dose of 40 Gy was chosen based on established practice in managing other benign conditions such as keloids and chronic psoriasis, which often require fractionated RT in the 30 to 40 Gy range to achieve durable response.13,14,20 Histologically, GF is marked by a dense dermal infiltrate of eosinophils, neutrophils, plasma cells, and lymphocytes, situated amid leukocytoclastic vasculitis and fibrosis.3 Unlike proliferative keloids, GF lacks a clonogenic target prone to radiation-induced cell death.14 Instead, GF is sustained by immune dysregulation with cytokine cascades that attract eosinophils and perpetuate inflammation.3 This inflammatory amplification loop may escape durable control by radiation alone. Furthermore, dermal fibrosis and vascular remodeling may impair tissue responsiveness and reduce radiation efficacy. This case underscores that although modern RT is technically feasible and safe, its biological impact in GF remains limited. Future exploration of RT in conjunction with immunomodulators may be more promising than RT monotherapy. Conclusion While technically feasible and well tolerated, this case illustrates the limitations of EBRT in achieving durable control in GF and reinforces the need for further investigation into optimal management strategies for this rare entity. Despite dose escalation and contemporary planning, no durable response was achieved, and recurrence occurred within 12 weeks. The chronic inflammatory factors that are pathognomonic for GF may contribute to the radiation resistance of GF and suggest that adjunctive strategies, potentially those combining RT with immunomodulatory or anti-inflammatory agents, may hold greater promise than EBRT alone. Given the potential for long-term adverse effects, RT should be approached with caution in GF and reserved for exceptional circumstances where other therapies have failed or are contraindicated. Disclosures The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.